Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 165,119 shares changed hands during mid-day trading, an increase of 96% from the previous session's volume of 84,123 shares.The stock last traded at $24.57 and had previously closed at $23.81.
Analyst Upgrades and Downgrades
PHVS has been the subject of several research reports. JMP Securities cut their target price on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a research note on Wednesday, August 13th. Guggenheim initiated coverage on Pharvaris in a research note on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price for the company. Wedbush reaffirmed an "outperform" rating and issued a $27.00 target price on shares of Pharvaris in a research note on Thursday, June 5th. Finally, Zacks Research raised Pharvaris from a "strong sell" rating to a "hold" rating in a research note on Monday, August 18th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Pharvaris has a consensus rating of "Moderate Buy" and an average price target of $34.00.
Get Our Latest Research Report on Pharvaris
Pharvaris Stock Up 3.3%
The stock has a fifty day moving average of $22.32 and a 200-day moving average of $18.34.
Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07). As a group, research analysts anticipate that Pharvaris N.V. will post -2.71 EPS for the current year.
Hedge Funds Weigh In On Pharvaris
Several institutional investors and hedge funds have recently added to or reduced their stakes in PHVS. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Pharvaris in the 2nd quarter worth $57,000. JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after buying an additional 783 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Pharvaris during the 4th quarter worth approximately $152,000. Legal & General Group Plc grew its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock valued at $203,000 after acquiring an additional 1,695 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its position in Pharvaris by 38.0% during the 1st quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company's stock worth $221,000 after acquiring an additional 3,881 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
See Also
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.